Taysha gene therapies reports third quarter 2024 financial results and provides corporate update

High dose tsha-102 was generally well tolerated with no saes or dlts in two adolescent/adult patients and one pediatric patient as of data cutoff; idmc approved continued enrollment in cohort two (high dose) across both reveal trials; eight patients dosed to date (low dose=4, high dose=4)
TSHA Ratings Summary
TSHA Quant Ranking